Therapeutic Drug Monitoring of Long-Acting Injectable Antipsychotics as a Predictor of Relapse in Schizophrenia Spectrum Disorders: A 1-Year Pilot Study.
Journal
Therapeutic drug monitoring
ISSN: 1536-3694
Titre abrégé: Ther Drug Monit
Pays: United States
ID NLM: 7909660
Informations de publication
Date de publication:
01 12 2022
01 12 2022
Historique:
received:
21
02
2022
accepted:
21
03
2022
pubmed:
21
4
2022
medline:
16
11
2022
entrez:
20
4
2022
Statut:
ppublish
Résumé
Long-acting injectable antipsychotics (LAIs) have been shown to reduce acute episodes of schizophrenia spectrum disorders (SSDs). However, breakthrough relapses are frequent, possibly because of underdosing in clinical practice. In this framework, the advantages of therapeutic drug monitoring (TDM) may be overlooked. This study explored the association of low steady-state LAI levels with a higher risk of relapse in SSDs, despite the use of a licensed posology. Forty-eight clinically stable outpatients with SSD underwent LAI-TDM using liquid chromatography-mass spectrometry for routine observational purposes. Baseline anamnestic, pharmacological, and psychometric evaluations compared subjects with "under-range" versus "in-range" LAI serum levels; between-group comparisons for different LAI treatments were also performed. A binary logistic regression explored which baseline factors (age, sex, previous hospitalizations, psychopathology, specific LAI treatment, and underrange serum levels) predicted relapse during the next 12 months. Baseline comparisons did not show significant between-group differences, except for a higher percentage of underrange values in individuals receiving olanzapine pamoate. A total of 10 patients (20.8%) relapsed during the follow-up; only underrange LAI levels predicted the event (odds ratio 0.03, 95% confidence interval 0.01-0.36; P = 0.005). Even if relapse remains as a multifactorial event, LAI-TDM may identify subjects at risk for this negative outcome, thus optimizing antipsychotic maintenance treatment in the context of precision medicine. The finding of underrange LAI plasma levels in real-world practice should prompt adequate monitoring of clinically stable outpatients to identify the early signs of psychopathological deterioration.
Sections du résumé
BACKGROUND
Long-acting injectable antipsychotics (LAIs) have been shown to reduce acute episodes of schizophrenia spectrum disorders (SSDs). However, breakthrough relapses are frequent, possibly because of underdosing in clinical practice. In this framework, the advantages of therapeutic drug monitoring (TDM) may be overlooked. This study explored the association of low steady-state LAI levels with a higher risk of relapse in SSDs, despite the use of a licensed posology.
METHODS
Forty-eight clinically stable outpatients with SSD underwent LAI-TDM using liquid chromatography-mass spectrometry for routine observational purposes. Baseline anamnestic, pharmacological, and psychometric evaluations compared subjects with "under-range" versus "in-range" LAI serum levels; between-group comparisons for different LAI treatments were also performed. A binary logistic regression explored which baseline factors (age, sex, previous hospitalizations, psychopathology, specific LAI treatment, and underrange serum levels) predicted relapse during the next 12 months.
RESULTS
Baseline comparisons did not show significant between-group differences, except for a higher percentage of underrange values in individuals receiving olanzapine pamoate. A total of 10 patients (20.8%) relapsed during the follow-up; only underrange LAI levels predicted the event (odds ratio 0.03, 95% confidence interval 0.01-0.36; P = 0.005).
CONCLUSIONS
Even if relapse remains as a multifactorial event, LAI-TDM may identify subjects at risk for this negative outcome, thus optimizing antipsychotic maintenance treatment in the context of precision medicine. The finding of underrange LAI plasma levels in real-world practice should prompt adequate monitoring of clinically stable outpatients to identify the early signs of psychopathological deterioration.
Identifiants
pubmed: 35442940
doi: 10.1097/FTD.0000000000000990
pii: 00007691-202212000-00013
doi:
Substances chimiques
Antipsychotic Agents
0
Delayed-Action Preparations
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
805-810Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Owen MJ, Sawa A, Mortensen PB. Schizophrenia. Lancet. 2016;388:86–97.
Miller JN, Black DW. Schizoaffective disorder: a review. Ann Clin Psychiatry. 2019;31:47–53.
Emsley R, Chiliza B, Asmal L, et al. The nature of relapse in schizophrenia. BMC Psychiatry. 2013;13:50.
Clinical Guideline 178. Psychosis and Schizophrenia in Adults: Prevention and Management; National Institute for Clinical Excellence (NICE); 2014. Available at: https://www.nice.org.uk/guidance/cg178 . Accessed February 14, 2022.
Kane JM, Kishimoto T, Correll CU. Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. World Psychiatry. 2013;12:216–226.
Correll CU, Citrome L, Haddad PM, et al. The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence. J Clin Psychiatry. 2016;77:1–24.
De Risio A, Lang AP. History and therapeutic rationale of long acting antipsychotics. Curr Clin Pharmacol. 2014;9:39–52.
Correll CU, Lauriello J. Using long-acting injectable Antipsychotics to enhance the potential for recovery in schizophrenia. J Clin Psychiatry. 2020;81:MS19053AH5C.
Tiihonen J, Mittendorfer-Rutz E, Majak M, et al. Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia. JAMA Psychiatry. 2017;74:686–693.
Huang CY, Fang SC, Shao YJ. Comparison of long-acting injectable Antipsychotics with oral antipsychotics and suicide and all-cause mortality in patients with newly diagnosed schizophrenia. JAMA Netw Open. 2021;4:e218810.
Misawa F, Kishimoto T, Hagi K, et al. Safety and tolerability of long-acting injectable versus oral antipsychotics: a meta-analysis of randomized controlled studies comparing the same antipsychotics. Schizophr Res. 2016;176:220–230.
Emsley R, Asmal L, Rubio JM, et al. Predictors of psychosis breakthrough during 24 months of long-acting antipsychotic maintenance treatment in first episode schizophrenia. Schizophr Res. 2020;225:55–62.
Rubio JM, Schoretsanitis G, John M, et al. Psychosis relapse during treatment with long-acting injectable antipsychotics in individuals with schizophrenia-spectrum disorders: an individual participant data meta-analysis. Lancet Psychiatry. 2020;7:749–761.
Seppälä A, Pylvänäinen J, Lehtiniemi H, et al. Predictors of response to pharmacological treatments in treatment-resistant schizophrenia—a systematic review and meta-analysis. Schizophr Res. 2021;236:123–134.
Schoretsanitis G, Kane JM, Correll CU, et al. Predictors of lack of relapse after random discontinuation of oral and long-acting injectable antipsychotics in clinically stabilized patients with schizophrenia: a re-analysis of individual participant data. Schizophr Bull. 2022;48:296–306.
McCutcheon R, Beck K, D'Ambrosio E, et al. Antipsychotic plasma levels in the assessment of poor treatment response in schizophrenia. Acta Psychiatr Scand. 2018;137:39–46.
Hiemke C, Bergemann N, Clement HW, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51:9–62.
Taylor D. Psychopharmacology and adverse effects of antipsychotic long-acting injections: a review. Br J Psychiatry Suppl. 2009;52:S13–S19.
Spanarello S, La Ferla T. The pharmacokinetics of long-acting antipsychotic medications. Curr Clin Pharmacol. 2014;9:310–317.
Urban AE, Cubała WJ. Therapeutic drug monitoring of atypical antipsychotics. Psychiatr Pol. 2017;51:1059–1077.
Baldelli S, Clementi E, Cattaneo D. Can we rely on AGNP therapeutic targets also for LAI antipsychotics? Pharmacopsychiatry. 2018;51:270–271.
Schoretsanitis G, Baumann P, Conca A, et al. Therapeutic drug monitoring of long-acting injectable antipsychotic drugs. Ther Drug Monit. 2021;43:79–102.
Mauri MC, Maffini M, Di Pace C, et al. “Long-acting” olanzapine in maintenance therapy of schizophrenia: a study with plasma levels. Int J Psychiatry Clin Pract. 2015;19:99–105.
Mauri MC, Reggiori A, Minutillo A, et al. Paliperidone LAI and aripiprazole LAI plasma level monitoring in the prophylaxis of bipolar disorder type I with manic predominance. Pharmacopsychiatry. 2020;53:209–219.
Baldelli S, Mauri MC, Di Pace C, et al. Intraindividual and interindividual variability of olanzapine trough concentrations in patients treated with the long-acting injectable formulation. J Clin Psychopharmacol. 2018;38:365–369.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, VA: American Psychiatric Association; 2013.
Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261–276.
Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429–435.
Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382–389.
First MB, Williams JBW, Karg RS, et al. Structured clinical interview for DSM-5: Disorders, clinician version (SCID-5-CV). Arlington, VA: American Psychiatric Association.
Leucht S, Kane JM, Kissling W, et al. What does the PANSS mean? Schizophr Res. 2005;79:231–238.
Müller MJ, Himmerich H, Kienzle B, et al. Differentiating moderate and severe depression using the Montgomery–Åsberg depression rating scale (MADRS). J Affect Disord. 2003;77:255–260.
Lukasiewicz M, Gerard S, Besnard A, et al. Young Mania Rating Scale: how to interpret the numbers? Determination of a severity threshold and of the minimal clinically significant difference in the EMBLEM cohort. Int J Methods Psychiatr Res. 2013;22:46–58.
Olivares JM, Sermon J, Hemels M, et al. Definitions and drivers of relapse in patients with schizophrenia: a systematic literature review. Ann Gen Psychiatry. 2013;12:32.
IBM Corp. SPSS Statistics for Windows, Version 25.0. Armonk, NY: IBM Corp.; 2017.
Uchida H, Takeuchi H, Graff-Guerrero A, et al. Predicting dopamine D₂ receptor occupancy from plasma levels of antipsychotic drugs: a systematic review and pooled analysis. J Clin Psychopharmacol. 2011;31:318–325.
Lako IM, van den Heuvel ER, Knegtering H, et al. Estimating dopamine D₂ receptor occupancy for doses of 8 antipsychotics: a meta-analysis. J Clin Psychopharmacol. 2013;33:675–681.
Pietrini F, Tatini L, Santarelli G, et al. Self- and caregiver-perceived disability, subjective well-being, quality of life and psychopathology improvement in long-acting antipsychotic treatments: a 2-year follow-up study. Int J Psychiatry Clin Pract. 2021;25:307–315.
Eliasson E, Lindh JD, Malmström RE, et al. Therapeutic drug monitoring for tomorrow. Eur J Clin Pharmacol. 2013;69(suppl 1):25–32.
Collins FS, Varmus H. A New initiative on precision medicine. N Engl J Med. 2015;372:793–795.
Jann MW, Penzak SR. Long-acting injectable second-generation antipsychotics: an update and comparison between agents. CNS Drugs. 2018;32:241–257.
Baldelli S, Cheli S, Montrasio C, et al. Therapeutic drug monitoring and pharmacogenetics of antipsychotics and antidepressants in real life settings: a 5-year single centre experience. World J Biol Psychiatry. 2021;22:34–45.
Hýža M, Šilhán P, Češková E, et al. Plasma levels of long-acting injectable antipsychotics in outpatient care: a retrospective analysis. Neuropsychiatr Dis Treat. 2021;17:1069–1075.
Gex-Fabry M, Balant-Gorgia AE, Balant LP. Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication. Ther Drug Monit. 2003;25:46–53.
Mitchell M, Kothare P, Bergstrom R, et al. Single- and multiple-dose pharmacokinetic, safety, and tolerability profiles of olanzapine long-acting injection: an open-label, multicenter, nonrandomized study in patients with schizophrenia. Clin Ther. 2013;35:1890–1908.
Predmore Z, Mattke S, Horvitz-Lennon M. Potential benefits to patients and payers from increased measurement of antipsychotic plasma levels in the management of schizophrenia. Psychiatr Serv. 2018;69:12–14.
Kaplan G, Casoy J, Zummo J. Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia. Patient Prefer Adherence. 2013;7:1171–1180.
Pacchiarotti I, Tiihonen J, Kotzalidis GD, et al. Long-acting injectable antipsychotics (LAIs) for maintenance treatment of bipolar and schizoaffective disorders: a systematic review. Eur Neuropsychopharmacol. 2019;29:457–470.
Schoretsanitis G, Kane JM, Correll CU, et al. Blood levels to optimize antipsychotic treatment in clinical practice: a joint consensus statement of the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie. J Clin Psychiatry. 2020;81:19cs13169.
Stingl JC, Brockmöller J, Viviani R. Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function. Mol Psychiatry. 2013;18:273–287.
Tveito M, Molden E, Høiseth G, et al. Impact of age and CYP2D6 genetics on exposure of aripiprazole and dehydroaripiprazole in patients using long-acting injectable versus oral formulation: relevance of poor and intermediate metabolizer status. Eur J Clin Pharmacol. 2020;76:41–49.
Preskorn SH. Therapeutic Drug Monitoring (TDM) in psychiatry (part I): why studies attempting to correlate drug concentration and antidepressant response don't work. J Psychiatr Pract. 2014;20:133–137.